Drugmaker Bets Big on Biopharma
A Chinese drugmaker plans to issue more than 1 billion yuan ($151.85 million) in bonds to build a new biopharmaceutical industrial park in the eastern city of Hangzhou.
The bond issuance makes Zhejiang Huahai Pharmaceutical Co. Ltd. just the latest of an army of biotech companies to invest big in biopharmaceutical research and development.
Huahai Pharmaceutical, whose major business is providing active ingredients for drugs to foreign and domestic pharmaceutical companies, announced it will issue 1.8 billion yuan in convertible bonds, 68% of which will be used to fund the biopharmaceutical park in Hangzhou, the capital of Zhejiang province.
The company will fund three other projects with the remainder.
In late 2011, the Ministry of Science and Technology projected the biology industry will grow 15% annually through to 2015. In January this year, China’s National Development and Reform Commission forecast that the output of China’s drug companies will hit 600 billion yuan by the end of the decade.
Following the political winds, venture capital funding in Chinese biopharma companies from 2012 to 2016 surged more than sixteenfold to more than $1 billion, according to BioCentury’s online intelligence service BCIQ.
In 2013, Huahai Pharmaceutical signed a partnership with U.S. biotech drugmaker Oncobiologics Inc. to secure the marketing rights for four drugs in China. The pair also planned to set up a joint venture in the U.S. for drug development.
However, the two companies have since scaled back the deal so that Huahai Pharmaceutical only has the rights to two drugs. The planned joint venture was also scrapped due to a “market change,” the Chinese company said in a filing to the Shanghai Stock Exchange in February 2016.
The Chinese drug supplier has shown a revived interest in biopharma this year. In May, it invested 36 million yuan in Chinese biopharma developer Hangzhou DAC Biotech Co. Ltd., and earlier this month it bought a stake in South Korean peer Eutilex Co. Ltd.
Contact reporter Coco Feng (firstname.lastname@example.org)
Oct 30 06:09 PM
Oct 30 05:58 PM
Oct 30 02:07 PM
Oct 30 01:03 PM
Oct 30 12:24 PM
Oct 30 11:26 AM
Oct 29 07:18 PM
Oct 29 04:59 PM
Oct 29 04:53 PM
Oct 29 01:03 PM
Oct 29 10:29 AM
Oct 29 12:36 AM
Oct 28 06:09 PM
Oct 28 06:08 PM
Oct 28 05:37 PM
- 1Semiconductor Tech Trends Favor China in the Long Term
- 2Cover Story: A Fugitive Businessman’s High-Profile Bet in Myanmar
- 3Financial Sector Should Avoid ‘Wrong Paths’ of Speculation, Bubbles and Ponzi Schemes, Vice President Says
- 4Analysis: Jack Ma Needs a Refresher on How Financial Regulation Works
- 5In Depth: Why Was a Shanghai Zoo Worker Killed in a Bear Attack?
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas